• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Predictions for Takeda 2013

Quote
Anonymous said:
Hey Zippy, while you are in Google take a look at the partnership co entered into with Quintiles and Covance. Wait; aren't those contract sales companies?
Click to expand...

Zippy, buttercup, sparky. Listen Mr Roll Tide doomsayer. I am still waiting to fight you whenever you are ready to get your Takeda Legacy beatdown. I am thrilled you are no longer working here, but wondering why you still choose to spend all your days checking this board and posting scary layoff rumors??
 




Anonymous said:
Zippy, buttercup, sparky. Listen Mr Roll Tide doomsayer. I am still waiting to fight you whenever you are ready to get your Takeda Legacy beatdown. I am thrilled you are no longer working here, but wondering why you still choose to spend all your days checking this board and posting scary layoff rumors??
Click to expand...

Because you spend all of your days reading it.
 




Anonymous said:
Zippy, buttercup, sparky. Listen Mr Roll Tide doomsayer. I am still waiting to fight you whenever you are ready to get your Takeda Legacy beatdown. I am thrilled you are no longer working here, but wondering why you still choose to spend all your days checking this board and posting scary layoff rumors??
Click to expand...

Zippydi Doo Daa Beatch
 




New drugs will only delay our cutbacks by a short while until upper management sees that the demand for these new "me too" products are not nearly as big a money maker as they hoped in order to keep all the sales reps we have on board at this time. The picture should become clearer to them towards the end of the year & that's when things are going to start to shake up.
 








So true, we all pretty much know that these new products are not going to be the cash cow that corporate wants it to be, but at least it buys a little more time to keep drawing that salary until mgt. sees what's going on & the hammer drops after 9-12 months or so.
 








Anonymous said:
So true, we all pretty much know that these new products are not going to be the cash cow that corporate wants it to be, but at least it buys a little more time to keep drawing that salary until mgt. sees what's going on & the hammer drops after 9-12 months or so.
Click to expand...

Lets not forget they did layoffs while Edarbi reps were in home study for edarbyclor, only to have to retrain many reps on both products after the RIF.
 








Guess somebody is going to be right here, but just can't say for sure if RIF will be soon or in 9-12 months as someone else has speculated. Just feel sure that cutbacks are certain & my DM agrees that this is probable. However, I don't feel cuts will be massive as some on here are trying to say. Probably in the neighborhood of 20% or so & then corporate can re-evaluate down the road again if we are still rep heavy or just right.
 




Anonymous said:
Guess somebody is going to be right here, but just can't say for sure if RIF will be soon or in 9-12 months as someone else has speculated. Just feel sure that cutbacks are certain & my DM agrees that this is probable. However, I don't feel cuts will be massive as some on here are trying to say. Probably in the neighborhood of 20% or so & then corporate can re-evaluate down the road again if we are still rep heavy or just right.
Click to expand...

lol, I love reading this crap. Cutbacks are certain, why? Please people, explain why there will be layoffs? Remember, we are not increasing our sales force for any launches, so why will we have layoffs when we just had an approval of a new drug and a few more on the way? We currently use a contract sales force until the end of March and we already had layoffs due to Actos and the Nycomed transaction? So I ask again, why will Takeda have a 20% layoff?

Not drinking the kool aid, I just don't see it but keep trolling
 




Agree that can't guarantee one way or the other that we will have or won't have layoffs & appears the same jerk keeps coming on here asking for "proof", but no way to give proof until 6-9 months out & company sees how new products are being accepted and prescribed. If doing as well as company hopes then rep count probably stay the same whereas if numbers not meeting anticipated sales figures then company will probably have no choice but to cutback to level out the $$ being lost due to low sales results. No way anyone can tell you now which way this will go & even the poster who keeps telling us that won't be any RIF for this reason or that reason due to new products is also just speculating as they also don't know what sales results will be down the road. All they can do is come up with the same line about new products, blau, blau, but new products don't always guarantee sales success if access is poor, high cost, etc. so these new products may not meet expectations, even if same poster keeps saying docs have been waiting for this for 5 yrs, but if difficult to prescribe due to managed care push-backs, etc. then just watch how fast these docs that have been waiting for it for 5 yrs jump ship. Again,no one on either side of this argument can prove one way or the other that there will be or won't be layoffs, just guessing on both sides so be patient & wait the 6-9 month & who ever if right can come back on here & say "I told you so".
 




Anonymous said:
lol, I love reading this crap. Cutbacks are certain, why? Please people, explain why there will be layoffs? Remember, we are not increasing our sales force for any launches, so why will we have layoffs when we just had an approval of a new drug and a few more on the way? We currently use a contract sales force until the end of March and we already had layoffs due to Actos and the Nycomed transaction? So I ask again, why will Takeda have a 20% layoff?

Not drinking the kool aid, I just don't see it but keep trolling
Click to expand...

Simple look around your pod count how many reps there are. That count could be kept if you had a 5B drug, these products will not generate enough to cover paying the head count. Chicago/Japan were waiting to see if drugs were approved so the short term cuts will be less than if drugs had not been approved, now they know what % to cut. Simple
 




Yo Ho Ho & away we go - now let's all just sit back & see who is right. Do we get a small cutback soon, do we get a larger cutback later or do we stay just where we are. Someone's going to be right. Just watch the numbers on our new products to see how they are doing nationally over the next few months & that will give you a little idea of what to expect.
 




Anonymous said:
Yo Ho Ho & away we go - now let's all just sit back & see who is right. Do we get a small cutback soon, do we get a larger cutback later or do we stay just where we are. Someone's going to be right. Just watch the numbers on our new products to see how they are doing nationally over the next few months & that will give you a little idea of what to expect.
Click to expand...

You guys on here claiming there "might" be layoffs base your response off nothing. I keep asking why do you think this is happening because it is obvious you don't have a clue. Do you even know what Takeda is forecasting for the Alo family? Or for that matter any of our drugs? Come on here with something specific. It was pretty obvious the last two time's we had layoffs, I just don't see it in the near future. And for those that are going to point to people getting axed while they were training for Edarbi, we knew that was coming because of the Nycomed deal. And before that, we grew too big for the launch of Alo and it didn't get approved. Thinking we were going to be a diabetes company. Things have changed.
 




Anonymous said:
Simple look around your pod count how many reps there are. That count could be kept if you had a 5B drug, these products will not generate enough to cover paying the head count. Chicago/Japan were waiting to see if drugs were approved so the short term cuts will be less than if drugs had not been approved, now they know what % to cut. Simple
Click to expand...

We are structured as a 5 billion dollar year company???? Really???? So you are telling me we are the same size we were in 2010???? Alo is looking at $400-$500 million product per, if that. Takeda has prepared to be a $1.2 billion company the next 2 years and then we will see.
 




Anonymous said:
We are structured as a 5 billion dollar year company???? Really???? So you are telling me we are the same size we were in 2010???? Alo is looking at $400-$500 million product per, if that. Takeda has prepared to be a $1.2 billion company the next 2 years and then we will see.
Click to expand...

If the co is dumb enough to have 5 to 7 reps per pod stepping over each other selling same product you are in trouble Drs will not allow it. $1.2 B does not support the number of field personnel you now have, if you can't see that? WOW
 




Agree with Poster #95 that we probably won't have layoffs in the "near future" (be no one can even guarantee that), but it's after we have been selling our new products down the road (10-12 mo) is when we should be concerned. If sales are doing great then all should be okay, but if not then layoffs are a distinct possibility. Normally with a new product company sets goals at a rapid growth rate since they are basing the growth off of a 0% market share & it is later when they reduce the rapid growth escalation that they expect when the product us newer. If this rapid growth does not occur to the companies satisfaction then layoffs are a strong possibility. Don't know how much plainer can put this to the one who keeps wanting someone to agree with them that everything is ok. If reps do their job well & sales are excellent then probably no cut backs, but if sales do not meet corporate expectations then he will be eating his words when they announce that a RIF will be necessary.
 












Top Bottom
Back
Quote